Johnson & Johnson Aktie News

The Wasatch Global Value Fund - Investor Class gained 6.36% in the third quarter of 2025, outperforming the MSCI All Country World Value Index, which added 6.13%. Leading contributors to the Fund's performance included Chinese e-commerce giant Alibaba Group. Leading detractors from Fund performance for the quarter included Centene Corp.

Johnson & Johnson is a financial fortress with a solid pipeline and portfolio. Coca-Cola has an asset-light model that drives its profitability.

Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.

The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.

Last month, Johnson & Johnson surged following a well-received quarterly earnings release. Despite a sluggish start to November, a spate of positive news has since sent the healthcare stock's shares to new highs.

J&J beat Wall Street estimates on sales and profits in the third quarter. The company recently announced the acquisition of a biotech with an innovative cancer treatment.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

At one point in early November, the Dow Jones Industrial Average (DJIA) briefly topped 48,000 for the first time ever. At different times in 2025, the NASDAQ and S&P 500 have made new all-time highs (ATHs).